NIH researcher to face charges over consulting fees

Share this article:
Federal prosecutors have charged a government Alzheimer’s researcher with engaging in a conflict of interest by earning $285,000 in private consulting fees from Pfizer, the Associated Press reported. The National Institutes of Health’s Dr. Trey Sunderland was accused of performing the consulting work that improperly overlapped with his government duties. The conflict-of-interest charge, filed in US District Court in Baltimore, carries a maximum of one year in prison and a $100,000 fine. Court papers said that Sunderland failed to get proper approval from NIH for his consulting work and didn’t properly report $285,000 in consulting fees and travel money from Pfizer that “directly related” to his federal research responsibilities. Sunderland’s case was highlighted during a congressional investigation that got under way more than two years ago. The investigation examined the large number of NIH scientists who earned money moonlighting as consultants for private pharma and biotech firms. Sunderland’s attorney, Robert Muse, and the NIH declined to comment to the AP on the development. Sunderland is scheduled to appear in court in Baltimore on Friday.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...